依诺妥珠单抗

依诺妥珠单抗INN:Enoblituzumab;开发代号:MGA271)是一种单克隆抗体,设计用于治疗癌症。[1]该药物是一种人源化IgG1κ单克隆抗体,可识别人类B7-H3(免疫调节剂B7家族的成员)。[2]

依诺妥珠单抗
单克隆抗体
种类?
目標B7-H3
臨床資料
其他名稱MGA271
ATC碼
  • 未分配
识别信息
CAS号1353485-38-7
ChemSpider
  • none
UNII
KEGG
化学信息
化学式C6474H9990N1726O2030S42
摩尔质量145,829.71 g·mol−1

该药物由MacroGenics公司开发。[3]

参考资料

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Enoblituzumab, American Medical Association.
  2. ^ Aggarwal, Charu; Prawira, Amy; Antonia, Scott; Rahma, Osama; Tolcher, Anthony; Cohen, Roger B.; Lou, Yanyan; Hauke, Ralph; Vogelzang, Nicholas; P Zandberg, Dan; Kalebasty, Arash Rezazadeh. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial. Journal for Immunotherapy of Cancer. 2022-04, 10 (4) [2024-03-12]. ISSN 2051-1426. PMC 9006844 . PMID 35414591. doi:10.1136/jitc-2021-004424. (原始内容存档于2024-06-16). 
  3. ^ Enoblituzumab (anti-B7-H3) – MacroGenics. macrogenics.com. [2024-03-12]. (原始内容存档于2024-03-12).